|
|
|
| |
Discovery & Pipeline
Thrombotargets has developed and adapted to High Throughput Screening a new family of biological assays capable to simultaneously quantify clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms,  , Thrombotargets is continuously creating a novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
|
|
News
| Thrombotargets Corp and KBI Biopharma announce GMP Phase I/II Manufacturing Contract for TT-103MH |
| • Thrombotargets presents the new products' pipeline during the investors´ annual meeting 2008. |
| • Thrombotargets receives the “Premi Ciutat de Barcelona” award 2007. |
Upcoming events
| • Thrombotargets Corp. will attend BIO-Europe Spring® 2008, the International Partnering Conference, Madrid, Spain, 2008. |
|
|
|